Gerald Liew1, Nichole Joachim2, Paul Mitchell2, George Burlutsky2, Jie Jin Wang2. 1. Centre for Vision Research, Department of Ophthalmology, Westmead Hospital, the Westmead Millennium Institute for Medical Research, University of Sydney, Sydney, Australia. Electronic address: gerald.liew@sydney.edu.au. 2. Centre for Vision Research, Department of Ophthalmology, Westmead Hospital, the Westmead Millennium Institute for Medical Research, University of Sydney, Sydney, Australia.
Abstract
PURPOSE: Most classification systems for age-related macular degeneration (AMD) were developed from patients in clinical trials. We aimed to validate the Age-Related Eye Diseases Study (AREDS) simplified severity scale of AMD classification using 5- and 10-year incident late AMD data from the population-based Blue Mountains Eye Study (BMES) cohort. DESIGN: Comparative study of population-based cohort and clinical trial. PARTICIPANTS: Blue Mountains Eye Study participants 40 to 97 years of age at baseline (n = 2134) and AREDS participants 55 to 80 years of age (n = 3640). METHODS: In the BMES, AMD lesions were graded from stereoscopic color photographs and were classified according to the AREDS simplified severity scale. The AREDS simplified scale calculates a risk score based on the number of early AMD risk factors (large drusen and pigment abnormalities) in both eyes that can range from 0 to 4. MAIN OUTCOME MEASURES: Five- and 10-year incident late AMD (presence of geographic atrophy or choroidal neovascularization). RESULTS: The AREDS simplified scale performed similarly when applied to both the BMES population-based participants and the AREDS clinical trial-based participants in predicting 5- and 10-year incidence of late AMD. For scores 0 to 4, the 5-year incidence rates for the BMES compared with the AREDS were 0.2% versus 0.4%, 3.1% versus 3.1%, 12.1% versus 11.8%, 13.5% versus 25.9%, and 47.1% versus 47.3%, respectively. The corresponding 10-year incidence rates for the BMES compared with the AREDS were 0.7% versus 1.5%, 7.3% versus 8.4%, 36.6% versus 27.6%, 20.0% versus 52.7%, and 75.0% versus 71.4%, respectively. CONCLUSIONS: The AREDS simplified severity scale classified late AMD risk levels similarly when applied to population-based and clinical trial samples. These results support the robustness of the AREDS simplified severity scale.
PURPOSE: Most classification systems for age-related macular degeneration (AMD) were developed from patients in clinical trials. We aimed to validate the Age-Related Eye Diseases Study (AREDS) simplified severity scale of AMD classification using 5- and 10-year incident late AMD data from the population-based Blue Mountains Eye Study (BMES) cohort. DESIGN: Comparative study of population-based cohort and clinical trial. PARTICIPANTS: Blue Mountains Eye Study participants 40 to 97 years of age at baseline (n = 2134) and AREDS participants 55 to 80 years of age (n = 3640). METHODS: In the BMES, AMD lesions were graded from stereoscopic color photographs and were classified according to the AREDS simplified severity scale. The AREDS simplified scale calculates a risk score based on the number of early AMD risk factors (large drusen and pigment abnormalities) in both eyes that can range from 0 to 4. MAIN OUTCOME MEASURES: Five- and 10-year incident late AMD (presence of geographic atrophy or choroidal neovascularization). RESULTS: The AREDS simplified scale performed similarly when applied to both the BMES population-based participants and the AREDS clinical trial-based participants in predicting 5- and 10-year incidence of late AMD. For scores 0 to 4, the 5-year incidence rates for the BMES compared with the AREDS were 0.2% versus 0.4%, 3.1% versus 3.1%, 12.1% versus 11.8%, 13.5% versus 25.9%, and 47.1% versus 47.3%, respectively. The corresponding 10-year incidence rates for the BMES compared with the AREDS were 0.7% versus 1.5%, 7.3% versus 8.4%, 36.6% versus 27.6%, 20.0% versus 52.7%, and 75.0% versus 71.4%, respectively. CONCLUSIONS: The AREDS simplified severity scale classified late AMD risk levels similarly when applied to population-based and clinical trial samples. These results support the robustness of the AREDS simplified severity scale.
Authors: Kathleen Romond; Minhaj Alam; Sasha Kravets; Luis de Sisternes; Theodore Leng; Jennifer I Lim; Daniel Rubin; Joelle A Hallak Journal: Exp Biol Med (Maywood) Date: 2021-08-18
Authors: Valur Emilsson; Elias F Gudmundsson; Thorarinn Jonmundsson; Brynjolfur G Jonsson; Michael Twarog; Valborg Gudmundsdottir; Zhiguang Li; Nancy Finkel; Stephen Poor; Xin Liu; Robert Esterberg; Yiyun Zhang; Sandra Jose; Chia-Ling Huang; Sha-Mei Liao; Joseph Loureiro; Qin Zhang; Cynthia L Grosskreutz; Andrew A Nguyen; Qian Huang; Barrett Leehy; Rebecca Pitts; Thor Aspelund; John R Lamb; Fridbert Jonasson; Lenore J Launer; Mary Frances Cotch; Lori L Jennings; Vilmundur Gudnason; Tony E Walshe Journal: Nat Commun Date: 2022-06-13 Impact factor: 17.694
Authors: Caroline Brandl; Martina E Zimmermann; Felix Günther; Teresa Barth; Matthias Olden; Sabine C Schelter; Florian Kronenberg; Julika Loss; Helmut Küchenhoff; Horst Helbig; Bernhard H F Weber; Klaus J Stark; Iris M Heid Journal: Sci Rep Date: 2018-06-06 Impact factor: 4.379
Authors: Thomas J Heesterbeek; Eiko K de Jong; Ilhan E Acar; Joannes M M Groenewoud; Bart Liefers; Clara I Sánchez; Tunde Peto; Carel B Hoyng; Daniel Pauleikhoff; Hans W Hense; Anneke I den Hollander Journal: Sci Rep Date: 2019-04-29 Impact factor: 4.379